Needham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Myriad Genetics (MYGN) PT Lowered to $32 at Deutsche BankFebruary 6, 2019 5:09 AM Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue OutlookFebruary 5, 2019 4:31 PM Form 8-K MYRIAD GENETICS INC For: Feb 05February 5, 2019 4:12 PM Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial ResultsFebruary 5, 2019 4:05 PM